BENSON CAPITAL PARTNERS ANNOUNCES FIRST INVESTMENT IN AXOSIM, INC. AxoSim, Inc, Provider of BrainSim™ and NerveSim™ Neurological Drug Discovery Platforms Teams with Benson Capital Partners and Jefferson Capital Partners For Immediate Release: November 5, 2020 […]
Read More
October 30, 2020 –Two grants from the DoD Congressionally Directed Medical Research Program and the National Institutes of Health awarded to AxoSim– –The CDMRP grant will support the development of a ALS NerveSim™ model to […]
Read More
AxoSim Scientist, Wesley Anderson, will be a Rapid Fire speaker at the 2020 AAPS PharmSci 360 Conference on Tuesday, November 3rd at 9:30am EST. His presentation is titled Development and Qualification of a Novel In […]
Read More
On Wednesday, September 30th, AxoSim Lead Scientist, Anup Sharma, PhD, spoke at our interactive webinar: Human Schwann Cells: Importance for Peripheral Neuropathy Preclinical Research. During this webinar, Dr. Sharma spoke about AxoSim’s Human Peripheral Co-Culture […]
Read More
High Throughput, Human Data: AxoSim’s Human Peripheral Co-Culture Assay In addition to our 3D NerveSim™ and BrainSim™ models, AxoSim also performs a variety of cell-based 2D assays including our new Human Schwann Cell and iPSC-derived […]
Read More
Introducing our newest SimLab Service: Human Co-Culture Peripheral Assay We are excited to launch our newest assay which uses human Schwann cells and iPSC-derived neurons to recapitulate the results one can expect to see from […]
Read More
On Wednesday, September 16th at 11:00am EST, AxoSim CEO, Dr. Lowry Curley will be giving a dynamic poster presentation at Safety Pharmacology Society’s (SPS) Annual Meeting, held virtually this year. The poster, #026, is entitled […]
Read More
Over 90% of neurological drugs that are successfully tested in animals fail once they reach human clinical trials. Therefore, there is a need for new, clinically relevant, preclinical testing models that mimic the human nervous […]
Read More
On July 28, 2020, AxoSim held a webinar which explored the need for new, predictive assays to better assess ADCs’ effects on peripheral neuropathy. Rakesh Dixit, PhD, DABT, elaborated on his 30 plus years of […]
Read More
On Tuesday, July 28th, AxoSim is hosting a webinar in collaboration with Rakesh Dixit, PhD, DABT, President and CEO of Bionavigen. This interactive webinar, entitled ADCs and Peripheral Neuropathy: The Need for New, Predictive Assays, […]
Read More